22157.jpg
Global Rheumatoid Arthritis Diagnosis Tests Market Report 2021: Market to Reach $766.7 Million by 2026 - Serology Segment to Account for $561.3 Million
08 oct. 2021 05h08 HE | Research and Markets
Dublin, Oct. 08, 2021 (GLOBE NEWSWIRE) -- The "Rheumatoid Arthritis Diagnosis Tests - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global...
TIP_link_300x300.jpg
TMS (Transcranial Magnetic Stimulator) Market ($2.02Bn by 2028) Growth Forecast at 8.8% CAGR During (2021-2028) - COVID-19 Impact and Global Analysis by TheInsightPartners.com
24 août 2021 15h44 HE | The Insight Partners
New York, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Transcranial Magnetic Stimulator (TMS) Market: Key InsightsAccording to our latest study on “Transcranial Magnetic Stimulator (TMS) Market Forecast to...
July 30, 2021 - ROSEN LOGO.jpg
ANVS BREAKING ALERT: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Annovis Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ANVS
19 août 2021 18h15 HE | The Rosen Law Firm PA
NEW YORK, Aug. 19, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
bioxcel-therapeutics-local-250x100.jpg
BioXcel Therapeutics Reports Second Quarter 2021 Financial Results and Recent Operational Highlights
10 août 2021 07h00 HE | BioXcel Therapeutics
Phase 3 study of BXCL501 for the acute treatment of agitation associated with dementia expected to begin in Q4 2021 PDUFA date of January 5, 2022 assigned to BXCL501 NDA for the acute treatment of...
bioxcel-therapeutics-local-250x100.jpg
BioXcel Therapeutics to Report Second Quarter 2021 Financial Results on August 10, 2021
28 juil. 2021 07h00 HE | BioXcel Therapeutics
NEW HAVEN, Conn., July 28, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI), a clinical-stage biopharmaceutical company utilizing artificial...
AB Science today announced that an abstract reporting results from its Phase 3 AB09004 study on Alzheimer’s disease has been selected for an oral presentation at the annual Alzheimer’s Association International Conference (AAIC)
22 juil. 2021 12h10 HE | AB Science
PRESS RELEASE AB SCIENCE TO PRESENT RESULTS FROM ITS PHASE III AB09004 STUDY IN MILD TO MODERATE ALZHEIMER’S DISEASE AT THE WORLD'S LARGEST CONFERENCE FOR ALZHEIMER’S AND DEMENTIA RESEARCH (AAIC...
AB Science annonce qu’un résumé de son étude de phase 3 dans la maladie d’Alzheimer a été sélectionné pour une présentation orale à la Alzheimer’s Association International Conference (AAIC)
22 juil. 2021 12h10 HE | AB Science
COMMUNIQUE DE PRESSE AB SCIENCE PRESENTERA LES RESULTATS DE SON ETUDE DE PHASE 3 AB09004 DANS LES FORMES LEGERES A MODEREES DE LA MALADIE D’ALZHEIMER LORS DE LA PLUS GRANDE CONFERENCE MONDIALE SUR LA...
bioxcel-therapeutics-local-250x100.jpg
BioXcel Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference
19 juil. 2021 07h30 HE | BioXcel Therapeutics
NEW HAVEN, Conn., July 19, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), today announced that Dr. Vimal Mehta, Ph.D., Founder and Chief Executive...
Revera debuts Unforgettable Ian’s journey in long term care
23 juin 2021 09h19 HE | Revera Inc.
Mississauga, Ontario, June 23, 2021 (GLOBE NEWSWIRE) -- Today, Revera, a leader in the senior living sector, is releasing Unforgettable Ian, a film about a remarkable resident at Revera’s Stoneridge...
logo-brainhq-hi-res-hori.png
$44 Million NIH Grant to See if Dementia Can Be Prevented
06 avr. 2021 08h00 HE | Posit Science
SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) -- Researchers at the University South Florida in Tampa have received a $44.4 million grant from the National Institutes of Health (NIH) for the...